- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06181929
A Prospective Study for the Early Diagnosis of Lung Cancer in Korean Females
A Prospective Study for the Early Diagnosis of Lung Cancer in Korean Females Who Are Never Smoker With a Family History of Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Interested individuals will contact a research coordinator who will help to assess for study eligibility. Individuals who are eligible and able to sign informed consent will then proceed to have a LDCT screening exam with a result reported by a radiologist approved to read lung cancer screening scans. Results of this screening test will be discussed with the subject and further recommendations will be given. Negative results will proceed to have repeat LDCT exams for two additional years. Positive results will be recommended to have further diagnostic work-up, and possible treatment. Those with positive findings may be recommended to repeat a LDCT at varied intervals (e.g. at 3 months, at 6 months, etc.) per Lung-RADS recommendations which can be conducted as a research LDCT or as standard-of-care.
In addition, blood draw collection for a plasma-based assay will be collected at baseline, first year and second year for all patients along with the repeated LDCT scans.
A medical history questionnaire containing questions regarding ethnicity, family history of lung cancer, environmental exposures including secondhand smoke exposure, and a residential district to estimate the exposure of PM2.5 or PM10 will be given to the patient at the initial visit after informed consent has been obtained (Appendix A). Questionnaire can be collected within 1 month from the baseline consent.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Um Sang-Won, PhD
- Phone Number: 82-2-3410-1645
- Email: sangwonum72@gmail.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 45-74 years old
- Korean female
- Never smoker defined as a lifetime exposure of less than 100 cigarettes
- Family history of lung cancer at first degree relatives (parents, siblings, or children)
Exclusion Criteria:
- Prior history of lung cancer.
- Diagnosis of any cancer within the past five years
- Participation in a cancer prevention trial.
- Present symptoms suggestive of current lung cancer, including: unexplained weight loss of over 5 kilograms within the last 12 months or unexplained hemoptysis.
- Medical or psychiatric condition precluding informed medical consent.
- History of LDCT screening, chest CT, PET or PET/CT scan within 10 years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: intervation group
LDCT screening exam
|
A subject can voluntarily discontinue active screening with LDCTs after the baseline LDCT is completed but will remain in study follow-up with follow-up calls in 12-month intervals for up to 10 years since initial consent
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lung cancer detection rate
Time Frame: up to 2years
|
detection rate
|
up to 2years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
distribution of lung cancer stages
Time Frame: up to 2years
|
number of lung cancer diagnosed, number of stage I, rate of surgery, rate of false positive
|
up to 2years
|
Estimation of the Early Detection Rate of Lung Cancer in Liquid Biopsy
Time Frame: up to 2years
|
cfDNA
|
up to 2years
|
incidence of lung cancer
Time Frame: up to 2years
|
Whether lung cancer is found in each screening test conducted for the first (baseline) and first and second years
|
up to 2years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
identification of potential predictive biomarkers of malignancy
Time Frame: up to 2years
|
EGFR mutation
|
up to 2years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Um Sang-Won, PhD, Samsung Medical Center
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20223-10-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Health Risk Behaviors
-
Istanbul University - Cerrahpasa (IUC)CompletedHealth Risk Behaviors | Reproductive Health | Sexual HealthTurkey
-
Edith Cowan UniversityFlinders University; The University of Western AustraliaNot yet recruitingHealth Risk Behaviors
-
Edith Cowan UniversityFlinders University; The University of Western AustraliaRecruiting
-
Edith Cowan UniversityFlinders University; The University of Western AustraliaCompleted
-
University Medicine GreifswaldUniversity Hospital Schleswig-Holstein; Deutsche Krebshilfe e.V., Bonn (Germany) and other collaboratorsCompleted
-
Edith Cowan UniversityFlinders University; The University of Western AustraliaCompleted
-
Laura RichardsonCompleted
-
University of Maryland Eastern ShoreCompletedHealth Risk Behaviors | Physical InactivityUnited States
-
University of CalgaryCanadian Institutes of Health Research (CIHR); British Columbia Farmers' Market...CompletedDiet, Healthy | Health Risk BehaviorsCanada
Clinical Trials on Low dose CT
-
Kyoung Ho Lee, MDSeoul National University Bundang Hospital; Ministry of Health & Welfare, Korea and other collaboratorsCompleted
-
Seoul National University Bundang HospitalGE Healthcare; National Research Foundation of KoreaCompletedAppendicitisKorea, Republic of
-
Yale UniversityAgency for Healthcare Research and Quality (AHRQ)Completed
-
University Hospital, GenevaCompleted
-
Oncology Teaching Hospital, BaghdadEnrolling by invitation
-
Hospices Civils de LyonCompletedTelangiectasia, Hereditary Hemorrhagic | Rendu Osler DiseaseFrance
-
The University of QueenslandActive, not recruitingNeoplasms | Respiratory Tract Diseases | Lung Diseases | Neoplasms by Site | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Non-small Cell Lung Cancer | Smokers at Risk of Lung CancerAustralia, Canada
-
Oslo University HospitalOdense University HospitalCompletedAbdominal Pain | Acute Pain | Acute Pancreatitis | Acute Cholecystitis | Acute AppendicitisNorway, Denmark
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaCompleted
-
University Health Network, TorontoCompleted